When Eli Lilly snapped up Scorpion Therapeutics' PI3Kα program earlier this year, the deal allowed Scorpion to spin out a new ...

Verve Therapeutics’ stock rallies by a record 80% on Eli Lilly’s premium purchase price for the drug-development company.

Verve Therapeutics stock jumped after pharmaceutical giant Eli Lilly said it was buying the gene-editing start-up for up to ...

Indianapolis: Eli Lilly and Company and Verve Therapeutics have announced a definitive agreement for Lilly to acquire Verve ...

Verve's leading programs aim to deliver lifelong cardiovascular risk reduction with a single dose by targeting genes strongly linked to cardiovascular disease Lilly's established capabilities in ...

Kraft Heinz said on Tuesday it would not launch products with artificial colours... Shares in the gene-editing starup Verve Therapeutics have soared more than 77 per... The total loan book of credit ...

Eli Lilly has struck a deal to buy Crispr gene-editing start-up Verve Therapeutics for up to $1.3bn, the latest acquisition ...

Eli Lilly agreed to acquire Verve Therapeutics for approximately $1 billion up front, adding a potential treatment for ...

Lilly has struck multiple partnership deals with gene-editing companies in the last two years to expand its portfolio beyond ...

U.S. stock index futures declined amid the ongoing Israel-Iran conflict, affecting global markets. Investor focus remains on ...

Eli Lilly said Tuesday that it will acquire Verve Therapeutics, a biotech developing gene-editing therapies for cardiovascular disease.